TickerFacts.

Agenus Inc (AGEN): Cost of Revenue

Annual figures by period end, from SEC filings.

$1.02M
Year ended 2025-12-31
$642.0K
Trailing 12 months to 2026-06-30
-54.1%
3-year compound annual growth
-15.3%
5-year compound annual growth
$10.57M2020-12-31: $2.35M2021-12-31: $3.47M2022-12-31: $10.57M2023-12-31: $3.11M2024-12-31: $486.0K2025-12-31: $1.02M$1.02M
2020-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$1.02M+110.3%2026-03-16, From 2025-01-01
2024-12-31$486.0K-84.4%2026-03-16, From 2024-01-01
2023-12-31$3.11M-70.6%2026-03-16, From 2023-01-01
2022-12-31$10.57M+204.6%2025-03-17, From 2022-01-01
2021-12-31$3.47M+47.7%2024-03-14, From 2021-01-01
2020-12-31$2.35Mn/a2023-03-16, From 2020-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Agenus Inc (AGEN)2025-12-31$1.02M+110.3%
ImmunityBio, Inc. (IBRX)2025-12-31$753.0Kn/a
REGENXBIO Inc. (RGNX)2024-12-31$33.57M-9.8%
Autolus Therapeutics plc (AUTL)2025-12-31$96.37M+746.3%
Recursion Pharmaceuticals, Inc. (RXRX)2025-12-31$70.95M+56.8%
Adaptimmune Therapeutics PLC (ADAPY)2024-12-31$70.0Kn/a
Compugen Ltd (CGEN)2025-12-31$9.25M+16.7%
Vir Biotechnology, Inc. (VIR)2025-12-31$26.0K-96.9%
Champions Oncology, Inc. (CSBR)2026-04-30$30.90M+8.8%

Compare AGEN, IBRX, RGNX, AUTL side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗